Gut Microbiota Changes in Inflammatory Bowel Diseases and Ankylosing Spondylitis

被引:14
|
作者
Cardoneanu, Anca [1 ]
Mihai, Catalina [2 ]
Rezus, Elena [1 ]
Burlui, Alexandra [1 ]
Popa, Iolanda [2 ]
Prelipcean, Cristina Cijevschi [2 ]
机构
[1] Grigore T Popa Univ Med & Pharm, Rehabil Clin Hosp, Iasi, Romania
[2] Grigore T Popa Univ Med & Pharm, Sf Spiridon Emergency Hosp, Inst Gastroenterol & Hepatol, Iasi, Romania
关键词
microbiota; inflammatory bowel disease; ankylosing spondylitis; gut dysbiosis; FAECALIBACTERIUM-PRAUSNITZII; FECAL MICROBIOTA; DYSBIOSIS; PATHOGENESIS; IMBALANCES; MICROFLORA; DIVERSITY; PROFILES;
D O I
10.15403/jgld-2823
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Both inflammatory bowel diseases (IBD) and ankylosing spondylitis (AS) can be considered chronic immune disorders sharing common etiopathogenetic mechanisms. Changes in the composition of the intestinal microbiota, which can lead to an abnormal mucosal response, could be the missing link between these two diseases. Our study evaluate the composition of intestinal microbiota and to characterize gut dysbiosis in patients with IBD and AS. Methods: We conducted a prospective case-control study that enrolled 124 patients [20 Crohn's disease (CD), 27 ulcerative colitis (UC), 28 AS, 17 IBD + AS and 32 controls). Intestinal microbiota analysis was performed by real-time polymerase chain reaction in stool samples. Results: The total quantity of bacteria was decreased in all investigated groups compared to the control group. In studied groups, we noticed an increased percentage of Bacteroides and Escherichia coli (E.coli) and a decreased percentage of Clostridium coccoides, Clostridium leptum, and Faecalibacterium prausnitzii compared to the control group. The percentages of Bifidobacterium (p=0.010) as well as Lactobacillus group (p=0.023) were higher in the L3 form of CD patients. In the E2 form of UC, the quantity of Bacteroides was much higher compared to the E3 form (p=0.004). In AS patients, significant correlations were observed only for the Bifidobacterium species, significantly increased in the axial form compared to peripheral disease (p=0.035). Statistically significant correlations were demonstrated between the Crohn Disease Activity Index score and the total bacterial group (p=0.023, r=-0.507), respectively Bacteroides (p=0.021, r=-0.511) and between the Mayo score and Lactobacillus (p=0.001), respectively E. coli (p=0.001). In IBD + AS group, the Crohn Disease Activity Index score was inversely correlated with the total bacterial group (p=0.010) and directly correlated with Lactobacillus (p=0.047). Conclusions: Intestinal dysbiosis is associated with both IBD and AS. In the association of IBD with AS, dysbiosis is intermediate, but it is associated with the more severe articular disease. Bifidobacterium and Lactobacillus (commonly used as probiotics!) were found to be increased in the association between active IBD and active AS. Further studies are needed to understand how dysbiosis regulates the gut immune system and contributes to intestinal and articular inflammation.
引用
收藏
页码:46 / 54
页数:9
相关论文
共 50 条
  • [31] Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases
    Candelli, Marcello
    Franza, Laura
    Pignataro, Giulia
    Ojetti, Veronica
    Covino, Marcello
    Piccioni, Andrea
    Gasbarrini, Antonio
    Franceschi, Francesco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
  • [32] The Role of Enterobacteriaceae in Gut Microbiota Dysbiosis in Inflammatory Bowel Diseases
    Baldelli, Valerio
    Scaldaferri, Franco
    Putignani, Lorenza
    Del Chierico, Federica
    MICROORGANISMS, 2021, 9 (04)
  • [33] Gut microbiota analyses of inflammatory bowel diseases from a representative Saudi population
    Alsulaiman, Raed M. M.
    Al-Quorain, Abdulaziz A. A.
    Al-Muhanna, Fahad A. A.
    Piotrowski, Stanley
    Kurdi, Ezzeddin A. A.
    Vatte, Chittibabu
    Alquorain, Ahmed A. A.
    Alfaraj, Noorah H. H.
    Alrezuk, Abdulaziz M. M.
    Robinson, Fred
    Dowdell, Alexa K. K.
    Alamri, Turki A. A.
    Hamilton, Lauren
    Lad, Hetal
    Gao, Hui
    Gandla, Divya
    Keating, Brendan J. J.
    Meng, Ryan
    Piening, Brian
    Al-Ali, Amein K. K.
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [34] Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases
    Pu, Dan
    Zhang, Zhe
    Feng, Baisui
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [35] Dynamic changes in gut microbiota under the influence of smoking and TNF-α-blocker in patients with ankylosing spondylitis
    Zhang, Fangze
    Ma, Cuili
    Zhang, Bin
    Bi, Liqi
    CLINICAL RHEUMATOLOGY, 2020, 39 (09) : 2653 - 2661
  • [36] Gut microbiota-microRNA interactions in ankylosing spondylitis
    Tavasolian, Fataneh
    Inman, Robert D.
    AUTOIMMUNITY REVIEWS, 2021, 20 (06)
  • [37] Distinctive gut microbiomes of ankylosing spondylitis and inflammatory bowel disease patients suggest differing roles in pathogenesis and correlate with disease activity
    P. R. Sternes
    L. Brett
    J. Phipps
    F. Ciccia
    T. Kenna
    E. de Guzman
    K. Zimmermann
    M. Morrison
    G. Holtmann
    E. Klingberg
    D. Mauro
    C. McIvor
    H. Forsblad-d’Elia
    M. A. Brown
    Arthritis Research & Therapy, 24
  • [38] The Role of Gut Microbiota in Inflammatory Bowel Disease-Current State of the Art
    Askari, Hassan
    Shojaei-Zarghani, Sara
    Raeis-Abdollahi, Ehsan
    Jahromi, Hossein Kargar
    Abdullahi, Payman Raise
    Daliri, Karim
    Tajbakhsh, Amir
    Rahmati, Leila
    Safarpour, Ali Reza
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2023, 23 (13) : 1376 - 1389
  • [39] Intestinal microbiota and inflammatory bowel diseases
    Eun, Chang Soo
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (09): : 588 - 595
  • [40] Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed
    Larussa, Tiziana
    Abenavoli, Ludovico
    Fabiano, Giulia
    Mancuso, Maria A.
    Polimeni, Natale
    Dumitrascu, Dan L.
    Luzza, Francesco
    MINERVA GASTROENTEROLOGY, 2021, 67 (04): : 357 - 368